Search Results 461-470 of 21322 for anti-TNF drugs

  1. Senolytic drugs boost key protective protein - Mayo Clinic News Network

    Senolytics developed at Mayo Clinic and given once clear the bloodstream of senescent or "zombie" cells. These cells contribute to multiple diseases and ...

  2. Dimethyl Fumarate (Oral Route) Description and Brand Names - Mayo Clinic

    Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Tecfidera. Descriptions. Dimethyl fumarate is used to treat ...

  3. Flecainide (Oral Route) Description and Brand Names - Mayo Clinic

    Flecainide belongs to the group of medicines known as antiarrhythmics. It works directly on the heart tissue and will slow the nerve impulses in the heart.

  4. Tizanidine (Oral Route) Description and Brand Names - Mayo Clinic

    Tizanidine does not cure these problems, but it may allow other treatment, such as physical therapy, to be more helpful in improving your condition.

  5. Carbidopa, Entacapone, And Levodopa (Oral Route) Description and Brand Names - Mayo Clinic

    This medicine is a combination of three different medicines. This medicine is known as a levodopa therapy. The difference between this medicine and other ...

  6. Vinblastine (Intravenous Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  7. Antibiotics: Are you misusing them? - Mayo Clinic

    ... drugs. This can lessen the growth of antibiotic resistance. What causes antibiotic resistance? Bacteria resist a drug when the bacteria change in some way.

  8. Metformin (Oral Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  9. Baclofen (Intrathecal Route) Description and Brand Names - Mayo Clinic

    Intrathecal baclofen does not cure these problems, but it may allow other treatment, such as physical therapy, to be more helpful in improving your condition.

  10. Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) - Mayo Clinic

    Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies. Exclusion Criteria: Current diagnosis of ...